RUSHNET INC - RSHN STOCK NEWS

RushNet, with stock symbol RSHN, announces its subsidiary heliosDX will present at the Emerging Growth Conference on October 27, 2021. This live presentation is geared toward individual and institutional investors, allowing real-time interaction with COO Yann Gerville-Réache and CEO Ashley Sweat. The presentation starts at 10:30 AM Eastern time and will last for 30 minutes, followed by a Q&A session. Interested parties can register to attend and access an archived version post-event.

RushNet, Inc. (OTC PINK:RSHN) announced a 15-month roadmap aimed at up-listing to Nasdaq. The company has recently acquired heliosDX, projected to generate $6 million in annual revenue, and Grandeza Healthcare, with estimated yearly revenue of $1.6 million. The roadmap includes a Reg A funding submission of up to $20 million, consolidation of financials, and major announcements regarding new healthcare technology and acquisitions. The company also plans to enhance its market capitalization while minimizing shareholder dilution.

Halberd Corp. and heliosDx have entered into a Scientific Collaboration Agreement aimed at developing new diagnostic technologies for effective disease management. This partnership, driven by Halberd's Chief Medical Officer, Dr. Patricio F. Reyes, focuses on improving diagnostic methods for neurological disorders and COVID-19. The collaboration is expected to enhance sample collection and processing, providing significant clinical outcomes and the potential for insurance reimbursement through CPT codes. Both companies are optimistic about the project's success and its impact on patient care.

RushNet, Inc (OTC PINK:RSHN) has reported significant growth through its subsidiaries heliosDX and Grandeza Healthcare. By September 10, 2021, heliosDX achieved a year-to-date revenue of $4,305,744.84 and is on track to exceed $6 million for the year. Grandeza Healthcare generated $1,275,218.71 in revenue, targeting $1,600,000 for 2021. Combined, they project an annual revenue run rate over $7,800,000. RushNet has also secured $20 million in funding for future acquisitions and growth initiatives, enhancing operational profitability and market reach.

RushNet, Inc. (OTC PINK:RSHN) announced a major milestone for its subsidiary heliosDX, surpassing 2020 annual revenue with $4,305,744.84 YTD and aiming for $6,000,000 by year-end 2021. This marks a significant growth from $2,639,454.58 in 2019 and $4,294,435.82 in 2020. Additional revenue from Grandeza Healthcare is projected to bring total annual revenue over $7,800,000. Recent acquisitions and upcoming funding of $20,000,000 are expected to support further growth.

RushNet, Inc. (OTC PINK: RSHN) has decided to retain heliosDX and Grandeza Healthcare as subsidiaries, reversing prior plans for a split-off. This strategic move aims to maximize shareholder value, with 2021 revenue forecasts exceeding $7.6 million. heliosDX anticipates revenues of $16 million from a pending lab acquisition, projecting $20 million to $25 million within 12 months. Grandeza expects to generate over $1.6 million this year. Both companies plan further acquisitions and potential uplisting to TSXV.

RushNet, Inc (OTC PINK:RSHN) announced a significant enhancement to its subsidiary heliosDX, integrating Artificial Intelligence (AI) into its diagnostic laboratory. The company is finalizing an agreement to adopt Arkstone OneChoice® technology, which uses machine-learning AI to improve treatment plans for infectious diseases. This technology analyzes various patient factors to provide personalized treatment recommendations. The integration is projected to enhance medical care and reduce undiagnosed diseases, marking a notable advancement in heliosDX's capabilities in the diagnostic space.

RushNet, Inc (OTC PINK:RSHN) announced its second acquisition, Grandeza Healthcare, a billing and coding company, on August 23, 2021. This follows the July acquisition of heliosDX, creating synergies between the two companies. Grandeza aims to expand its services and is expected to generate revenues of approximately $1.6 million for 2021. The combined revenue run rate of RushNet, including heliosDX, exceeds $7.6 million. Both acquisitions are considered strategic for RushNet's growth in the healthcare sector.

RushNet, Inc. (OTC PINK:RSHN) announces its intention to list on the TSX Venture Exchange alongside a split-off initiative for its subsidiary, heliosDX. Engaging qualified counsel, the company aims to enhance credibility and shareholder value. The TSX-V listing may provide liquidity for acquisitions and assist heliosDX in reaching a target of $50 million in annual revenue by the end of 2023. Despite facing hurdles in becoming a standalone entity, recent growth trends indicate positive developments.